The Scott M. Hammer Annual Update on HIV Management in New York, New York

Last Modified: Dec 12, 2024 @ 8:41 PM

Program Description

Join us for the highly anticipated IAS–USA annual course in New York, New York, for the most current and clinically relevant information in HIV care. Don’t miss out on the opportunity to engage with faculty and peers and to stay at the forefront of what’s new in HIV management. This dynamic live course will be in person at the NYU Skirball Center, and there will NOT be a simultaneous virtual component.

Highlights include updates from the Conference on Retroviruses and Opportunistic Infections (CROI) 2025; sexually transmitted infections (STIs) prevention, including the management and treatment of syphilis; review of the current state and understanding of long-acting drugs for the treatment and prevention of HIV; review of the screening and prevention of human papillomavirus (HPV)-related anal, cervical, and oropharyngeal cancers in people with HIV; and a case-based panel discussion on antiretroviral therapy. This course will also highlight feature the new primary care guidelines for persons with HIV and explore the best practices in hormone therapy management and strategies to incorporate transgender-competent health care into clinical practice.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Describe the most current data from recent HIV scientific conferences, including research on new and investigational antiretroviral drugs
• Describe the current epidemiology, clinical presentation, prevention, and management of relevant common STIs in adults with HIV
• Explore the evolving guidelines for HPV-related cancer screening in people with HIV and how emerging data will likely lead to additional changes
• Identify various important clinical manifestations of syphilis
• Apply the latest recommendations of the HIV Medicine Association of the Infectious Diseases Society of America (HIVMA/IDSA) Primary Care Guidance for Persons With HIV to optimize care engagement, medication adherence, and viral suppression in people with HIV
• Describe best practices in hormone therapy management

Topics

• Key updates from CROI 2025, including HIV cure and new drugs
• What’s new in STI and syphilis management, including doxycycline postexposure prophylaxis (doxyPEP), and vaccines
• Screening and prevention of anal, cervical, and oral/oropharyngeal cancers in people with HIV
• HIV prevention updates, including long-acting drugs
• 2024 Update of the HIVMA/IDSA Primary Care Guidance for Persons With HIV
• Gender-affirming hormone care
• Difficult cases in antiretroviral therapy

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.